<div id="readability-page-1"><p>Up about 12%, Tempus AI (NASDAQ:TEM) has been explosive.</p> <p>Helping, its volume just spiked to 18.6 million shares, as compared to its daily average volume of about 5.67 million. All thanks to three key catalysts.</p> <p><img src="https://imageproxy.pbkrs.com/https://247wallst.com/wp-content/uploads/2024/05/shutterstock_2339707233-scaled.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="2560" height="1440" original-src="https://imageproxy.pbkrs.com/https://247wallst.com/wp-content/uploads/2024/05/shutterstock_2339707233-scaled.jpg"/></p><p><img src="https://imageproxy.pbkrs.com/https://247wallst.com/wp-content/uploads/2025/01/Follow-Our-500000-AI-Portfolio-3.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="468" height="120" original-src="https://imageproxy.pbkrs.com/https://247wallst.com/wp-content/uploads/2025/01/Follow-Our-500000-AI-Portfolio-3.jpg"/></p> <h2><strong>Key Points About This Article</strong><strong> </strong></h2> <ul> <li>Up about 12%, Tempus AI (NASDAQ: TEM) is rocketing thanks to three key catalysts.</li> <li>One, Tempus AI just acquired Ambry Genetics.</li> <li>Two, Nancy Pelosi and Cathie Wood are bullish on Tempus AI.</li> <li>Three, TD Cowen just upgraded the TEM stock to a buy with a $74 price target.</li> <li>If you’re looking for more stock ideas, don’t forget to grab a copy of our <strong>“The Next NVIDIA” </strong>report that’s free. It details the war between NVIDIA and one stock that rose 114% in 2024. The report is loaded with research on top AI stocks and is available complimentary for a limited time.</li> </ul> <h2><strong>Catalyst No. 1: Tempus AI Just Acquired Ambry Genetics</strong></h2> <p>Tempus AI just acquired Ambry Genetics, a well-known leader in genetic testing, for $600 million, which includes $375 million in cash payments and $225 million in shares.</p> <p>And, according to Eric Lefkofsky, Founder and CEO of Tempus, the acquisition “complements our strategy of leveraging diagnostics and data to drive innovation, further strengthening our ability to deliver cutting-edge solutions to clinicians, patients, and life sciences companies.”</p> <p>It’s also expected to strengthen Tempus AI’s product offerings and accelerate its road to positive free cash flow and profitability. Plus, it’ll expose Tempus AI to even more genetic testing in specialties such as pediatrics and cardiology, which it didn’t have exposure to before.</p> <h2><strong>Catalyst No. 2: Nancy Pelosi is Bullish on Tempus AI</strong><strong> </strong></h2> <p>Nancy Pelosi took a stake in the TEM stock by buying 50 of the TEM January 2026 $20 call options in mid-January. Even Cathie Wood picked up about 600,000 shares across multiple funds last month.</p> <p>In fact, <strong><span>“Ark Invest’s interest in TEM began on December 6, when the ARK Genomic Revolution ETF made its initial purchase of shares in the healthcare technology company. Since then, Tempus AI has rapidly ascended within Ark’s portfolio, becoming the </span></strong>tenth-largest<strong><span> holding in the flagship Ark Innovation ETF. TEM now represents 3.2% of ARKK’s total assets, with a market value exceeding $265 million, as noted by Seeking Alpha.</span></strong></p> <h2><strong>Catalyst No. 3: TD Cowen Just Upgraded Tempus AI to a Buy</strong></h2> <p> Analysts at TD Cowen just upgraded the AI stock to a buy rating, with a price target of $74.</p> <p> According to the firm, the latest acquisition gives Tempus a $300 profitable germline testing lab. Plus, it’ll strengthen Tempus AI product offerings and help it expand into new territory. All while providing a clearer path to positive free cash flow. What’s not to like?</p> <p>The post Why Tempus AI (TEM) Is Soaring Today appeared first on 24/7 Wall St..</p></div>

<p>Tempus AI (NASDAQ:TEM) shares surged by 12%, driven by three key catalysts: the acquisition of Ambry Genetics for $600 million, endorsements from Nancy Pelosi and Cathie Wood, and an upgrade from TD Cowen to a buy rating with a $74 price target. The acquisition is expected to enhance Tempus's product offerings and accelerate its path to profitability, while the endorsements have increased investor interest, making TEM a significant holding in Ark Invest's portfolio.</p>

247wallst

Tempus AI

iShares Global Timber & Forestry UCITS ETF GBP

iShares S&P Global Timber Forestry